233 related articles for article (PubMed ID: 37564657)
1. Integrative multi-omics analyses unravel the immunological implication and prognostic significance of CXCL12 in breast cancer.
Gao ZJ; Fang Z; Yuan JP; Sun SR; Li B
Front Immunol; 2023; 14():1188351. PubMed ID: 37564657
[TBL] [Abstract][Full Text] [Related]
2. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
Front Immunol; 2022; 13():994019. PubMed ID: 36177006
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated fibroblast-derived gene signature discriminates distinct prognoses by integrated single-cell and bulk RNA-seq analyses in breast cancer.
Fang Z; Han YL; Gao ZJ; Yao F
Aging (Albany NY); 2024 May; 16(9):8279-8305. PubMed ID: 38728370
[TBL] [Abstract][Full Text] [Related]
4. Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer.
Yu Z; Zhu Y; Ji J
Medicine (Baltimore); 2023 Jul; 102(28):e34287. PubMed ID: 37443486
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
[TBL] [Abstract][Full Text] [Related]
6. Integrating single-cell and bulk transcriptomic analyses to develop a cancer-associated fibroblast-derived biomarker for predicting prognosis and therapeutic response in breast cancer.
Li C; Yang L; Zhang Y; Hou Q; Wang S; Lu S; Tao Y; Hu W; Zhao L
Front Immunol; 2023; 14():1307588. PubMed ID: 38235137
[TBL] [Abstract][Full Text] [Related]
7. Construction of cancer- associated fibroblasts related risk signature based on single-cell RNA-seq and bulk RNA-seq data in bladder urothelial carcinoma.
Liu Y; Jian J; Zhang Y; Wang L; Liu X; Chen Z
Front Oncol; 2023; 13():1170893. PubMed ID: 37124542
[TBL] [Abstract][Full Text] [Related]
8. Identification of a pyroptosis-related prognostic signature in breast cancer.
Chen H; Luo H; Wang J; Li J; Jiang Y
BMC Cancer; 2022 Apr; 22(1):429. PubMed ID: 35443644
[TBL] [Abstract][Full Text] [Related]
9. Identification of a centrosome-related prognostic signature for breast cancer.
Fang Z; Gao ZJ; Yu X; Sun SR; Yao F
Front Oncol; 2023; 13():1138049. PubMed ID: 37035151
[TBL] [Abstract][Full Text] [Related]
10. Identification of a basement membrane-related gene signature for predicting prognosis and estimating the tumor immune microenvironment in breast cancer.
Cai J; Zhang X; Xie W; Li Z; Liu W; Liu A
Front Endocrinol (Lausanne); 2022; 13():1065530. PubMed ID: 36531485
[TBL] [Abstract][Full Text] [Related]
11. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial DNA methylation is a predictor of immunotherapy response and prognosis in breast cancer: scRNA-seq and bulk-seq data insights.
Ma Y; Du J; Chen M; Gao N; Wang S; Mi Z; Wei X; Zhao J
Front Immunol; 2023; 14():1219652. PubMed ID: 37457713
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
14. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
15. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
Gao B; Wang Y; Lu S
Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
[TBL] [Abstract][Full Text] [Related]
16. A novel immune-related prognostic index for predicting breast cancer overall survival.
Yu X; Guo J; Zhou Q; Huang W; Xu C; Long X
Breast Cancer; 2021 Mar; 28(2):434-447. PubMed ID: 33146847
[TBL] [Abstract][Full Text] [Related]
17. A tumor microenvironment-related risk model for predicting the prognosis and tumor immunity of breast cancer patients.
Geng S; Fu Y; Fu S; Wu K
Front Immunol; 2022; 13():927565. PubMed ID: 36059555
[TBL] [Abstract][Full Text] [Related]
18. Multi-omics cluster defines the subtypes of CRC with distinct prognosis and tumor microenvironment.
Ma Y; Li J; Zhao X; Ji C; Hu W; Ma Y; Qu F; Sun Y; Zhang X
Eur J Med Res; 2024 Mar; 29(1):207. PubMed ID: 38549156
[TBL] [Abstract][Full Text] [Related]
19. Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients.
Hu B; Meng Y; Qu C; Wang BY; Xiu DR
Front Immunol; 2022; 13():1018413. PubMed ID: 36300104
[TBL] [Abstract][Full Text] [Related]
20. Multi-omics analysis elucidates the relationship between intratumor microbiome and host immune heterogeneity in breast cancer.
Li J; Zhang Y; Cai Y; Yao P; Jia Y; Wei X; Du C; Zhang S
Microbiol Spectr; 2024 Apr; 12(4):e0410423. PubMed ID: 38442004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
